Lifeline Biotechnologies, Inc. CEO Reveals New Information in Audio Interview on Stockbully.com

Reno, NV - April 29, 2008 – Lifeline Biotechnologies, Inc. (OTCPK: LLBT) , a developer of innovative medical technology, today announced that CEO, Jim Holmes, was interviewed on www.stockbully.com. In the interview, Mr. Holmes discussed the current status of the Company's patented First Warning System™, a technology that could assist in the early, non-invasive detection of breast cancer.

Stockbully.com gives attention to emerging growth companies that seek more exposure in the investment community. Stockbully.com is a multimedia investor relation’s source that seeks out promising and mostly undiscovered companies in the market place and enables their clients to utilize multimedia marketing to gain exposure via the information highway.

“Throughout our extensive testing, we have accomplished significant improvements in detection percentages over that of mammograms. The First Warning System™ is currently going through additional adjustments, at the same time we have a very promising process that could change the face of breast cancer detection,” stated Lifeline Biotechnologies, Inc. President and CEO Jim Holmes. “Please visit our website (www.lbti.com) to stay updated on all of the recent events regarding our First Warning System™.”

About Stockbully.com

Stockbully.com differentiates itself from traditional investor relations businesses, in that it strives to take a long-term approach. It nurtures and supports promising emerging companies with the aim of growing and appreciating in value. Through exposure on the Internet, Stockbully.com enables its clients to secure a place in their respective sector. Clients with limited financial means can utilize multimedia marketing via the Internet to gain a competitive edge. For more information, please visit http://www.stockbully.com/. 

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: development of the First Warning System™’s interpretive, proprietary software, clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.

Contact:

e-media Direct, Inc.

Investor Relations

(866)284-2835

info@e-mediadirect.com